An Open-label, Single-arm, Phase I Clinical Trial to Evaluate the Safety and Efficacy of TX103 CAR-T Cells in Participants With Advanced Solid Tumors
Latest Information Update: 20 Nov 2025
At a glance
- Drugs TX 103 (Primary) ; TX 103 (Primary)
- Indications Colorectal cancer; Fallopian tube cancer; Head and neck cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Tcelltech Inc.
Most Recent Events
- 18 Jul 2024 New trial record